The same situation was observed in the GCF level of adiponectin at the 3-month follow-up in obese patients, but a significant increase in the GCF level of adiponectin was found in non-obese patients 3 months after the therapy, indicating that obesity may reduce the effectiveness of the treatment, while non-obese individuals may be more responsive to NSPT for anti-inflammation. This evidence concerns the gene ADIPOQ and obesity due to melanocortin 4 receptor deficiency.